

AGM results

Melbourne, Australia; 21 November 2019: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises that details of the resolutions and the proxies and votes received in respect of each resolution at its AGM today are set out in the attached proxy and voting summary.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.

VivaGel®: Starpharma's women's health product - VivaGel® BV is based on SPL7013, astodimer sodium, a proprietary dendrimer. VivaGel® BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe) and Fleurstat BVgel (Australia) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Japan under Okamoto's 003 brand, and in Australia and Canada under the LifeStyles Dual Protect® brand. The VivaGel® condom is approved in Europe.

DEP® - Dendrimer Enhanced Product®: Starpharma's DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has three internal DEP® products – DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan - in clinical development in patients with solid tumours. Starpharma's partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca's major marketed oncology medicines.

Starpharma.com | [Twitter](https://twitter.com/starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

Media

WE Buchan Consulting

Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

21 November 2019

The Chairman
STARPHARMA HOLDINGS LIMITED
4-6 Southamptom
Crescent
Abbotsford
VIC 3067 Australia

Poll Report

I, the Returning Officer appointed by you in connection with the voting by poll on the motions set out below at the Annual General Meeting of the Members of STARPHARMA HOLDINGS LIMITED held at RACV City Club, Level 2 (Bourke rooms 2 and 3), 501 Bourke Street, Melbourne, Victoria on 21 November 2019 at 4:00 PM, report as follows:

1 Adoption of Remuneration Report

	Number	%
Votes cast 'FOR' the motion	191,653,765	93.48
Votes cast 'AGAINST' the motion	13,357,358	6.52
TOTAL VOTES CAST	205,011,123	100.00
Votes "Abstained"	4,272,543	

The resolution was carried as an ordinary resolution.

2 Re-election of Ms Zita Peach

	Number	%
Votes cast 'FOR' the motion	203,044,251	96.23
Votes cast 'AGAINST' the motion	7,960,845	3.77
TOTAL VOTES CAST	211,005,096	100.00
Votes "Abstained"	4,867,598	

The resolution was carried as an ordinary resolution.

3 Approve Issue of Performance Rights to Dr Jacinth Fairley

	Number	%
Votes cast 'FOR' the motion	192,498,823	93.09
Votes cast 'AGAINST' the motion	14,297,037	6.91
TOTAL VOTES CAST	206,795,860	100.00
Votes "Abstained"	5,177,425	

The resolution was carried as an ordinary resolution.

David Squires
Returning Officer
Computershare Investor Services Pty Limited